↓ Skip to main content
What is this page? Embed badge

HIV Vaccines and Cure

Overview of attention for book
Cover of 'HIV Vaccines and Cure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 HIV Vaccine Efficacy Trials: RV144 and Beyond
  3. Altmetric Badge
    Chapter 2 HIV T-Cell Vaccines
  4. Altmetric Badge
    Chapter 3 HIV Broadly Neutralizing Antibodies: VRC01 and Beyond
  5. Altmetric Badge
    Chapter 4 Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine
  6. Altmetric Badge
    Chapter 5 Monkey Models and HIV Vaccine Research
  7. Altmetric Badge
    Chapter 6 Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level
  8. Altmetric Badge
    Chapter 7 HIV Persistence on Antiretroviral Therapy and Barriers to a Cure
  9. Altmetric Badge
    Chapter 8 The Molecular Biology of HIV Latency
  10. Altmetric Badge
    Chapter 9 Cellular Determinants of HIV Persistence on Antiretroviral Therapy
  11. Altmetric Badge
    Chapter 10 In Vitro and In Vivo Models of HIV Latency
  12. Altmetric Badge
    Chapter 11 Measuring HIV Persistence on Antiretroviral Therapy
  13. Altmetric Badge
    Chapter 12 Clinical Interventions in HIV Cure Research
Attention for Chapter 1: HIV Vaccine Efficacy Trials: RV144 and Beyond
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
video
1 YouTube creator

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
36 Mendeley
Summary X YouTube Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
HIV Vaccine Efficacy Trials: RV144 and Beyond
Chapter number 1
Book title
HIV Vaccines and Cure
Published in
Advances in experimental medicine and biology, January 2018
DOI 10.1007/978-981-13-0484-2_1
Pubmed ID
30030787
Book ISBNs
978-9-81-130483-5, 978-9-81-130484-2
Authors

Elizabeth Heger, Alexandra Schuetz, Sandhya Vasan, Heger, Elizabeth, Schuetz, Alexandra, Vasan, Sandhya

Abstract

Despite progress in antiretroviral therapy, pre-exposure prophylaxis, microbicides, and other preventive strategies, a vaccine to prevent HIV-1 infection remains desperately needed. Development of an effective vaccine is challenged by several immunologic features of HIV-1 evidenced by the failure of five of the six HIV-1 candidate vaccine efficacy trials to date. This chapter reviews these efficacy trials with a focus on the Phase 3 RV144 trial in Thailand, the only HIV-1 vaccine efficacy trial to show a moderate protective effect of 31% with respect to placebo administration. Although modest, this protection has allowed for the study of potential immunologic correlates of protection to improve development of future HIV-1 pox-protein and other vaccine strategies. Trials in Thailand and South Africa have built upon the RV144 framework to provide additional immunologic insights which enable current and future efficacy testing of related vaccine candidates.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 17%
Student > Ph. D. Student 6 17%
Student > Bachelor 5 14%
Student > Master 5 14%
Professor 1 3%
Other 1 3%
Unknown 12 33%
Readers by discipline Count As %
Immunology and Microbiology 5 14%
Biochemistry, Genetics and Molecular Biology 4 11%
Medicine and Dentistry 4 11%
Agricultural and Biological Sciences 4 11%
Nursing and Health Professions 2 6%
Other 3 8%
Unknown 14 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2022.
All research outputs
#18,649,743
of 23,932,398 outputs
Outputs from Advances in experimental medicine and biology
#3,221
of 5,068 outputs
Outputs of similar age
#318,456
of 447,921 outputs
Outputs of similar age from Advances in experimental medicine and biology
#139
of 235 outputs
Altmetric has tracked 23,932,398 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,068 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,921 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.